Metallothionein as a useful marker in Hodgkin lymphoma subclassification

Milena Penkowa; Brit Ladegaard Sørensen; Signe Lidou Nielsen; Per Boye Hansen

doi:10.1080/10428190802699340

Metallothionein as a useful marker in Hodgkin lymphoma subclassification

Milena Penkowa, Brit Ladegaard Sørensen, Signe Lidou Nielsen, Per Boye Hansen

6 Citations (Scopus)

Abstract

Metallothionein (MT) expression is considered to be a prognostic factor that promotes tumor resistance to apoptosis. In non-Hodgkin lymphomas, MT is differentially expressed and constitutes a risk factor. We have characterised MT in lymph nodes of Hodgkin lymphoma (HL) [patients with nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte-rich classical HL (LRCHL) and nodular lymphocyte predominant HL (NLPHL)] and in controls. MT expression is significantly and differentially altered in the HL subtypes. NSHL and MCHL show highly increased MT throughout the lymph node. In contrast, MT is barely increased in LRCHL relative to controls. NLPHL shows a distinct pattern of heterogeneous MT with increased MT in nodular areas surrounded by MT-negative tissue. The cellular MT sources are reactive, infiltrating (non-neoplastic) cells, whereas neoplastic cells are devoid of MT. We show for the first time that MT is differentially expressed in subclassified HL.

Original language	English
Journal	Leukemia and Lymphoma
Volume	50
Issue number	2
Pages (from-to)	200-10
Number of pages	10
ISSN	1042-8194
DOIs	https://doi.org/10.1080/10428190802699340
Publication status	Published - 2009

Access to Document

10.1080/10428190802699340

Cite this

@article{138c4b00832a11de8bc9000ea68e967b,

title = "Metallothionein as a useful marker in Hodgkin lymphoma subclassification",

abstract = "Metallothionein (MT) expression is considered to be a prognostic factor that promotes tumor resistance to apoptosis. In non-Hodgkin lymphomas, MT is differentially expressed and constitutes a risk factor. We have characterised MT in lymph nodes of Hodgkin lymphoma (HL) [patients with nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte-rich classical HL (LRCHL) and nodular lymphocyte predominant HL (NLPHL)] and in controls. MT expression is significantly and differentially altered in the HL subtypes. NSHL and MCHL show highly increased MT throughout the lymph node. In contrast, MT is barely increased in LRCHL relative to controls. NLPHL shows a distinct pattern of heterogeneous MT with increased MT in nodular areas surrounded by MT-negative tissue. The cellular MT sources are reactive, infiltrating (non-neoplastic) cells, whereas neoplastic cells are devoid of MT. We show for the first time that MT is differentially expressed in subclassified HL.",

author = "Milena Penkowa and S{\o}rensen, {Brit Ladegaard} and Nielsen, {Signe Lidou} and Hansen, {Per Boye}",

note = "Keywords: Biopsy; Hodgkin Disease; Humans; Metallothionein; Treatment Outcome; Tumor Markers, Biological",

year = "2009",

doi = "10.1080/10428190802699340",

language = "English",

volume = "50",

pages = "200--10",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Metallothionein as a useful marker in Hodgkin lymphoma subclassification

AU - Penkowa, Milena

AU - Sørensen, Brit Ladegaard

AU - Nielsen, Signe Lidou

AU - Hansen, Per Boye

N1 - Keywords: Biopsy; Hodgkin Disease; Humans; Metallothionein; Treatment Outcome; Tumor Markers, Biological

PY - 2009

Y1 - 2009

N2 - Metallothionein (MT) expression is considered to be a prognostic factor that promotes tumor resistance to apoptosis. In non-Hodgkin lymphomas, MT is differentially expressed and constitutes a risk factor. We have characterised MT in lymph nodes of Hodgkin lymphoma (HL) [patients with nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte-rich classical HL (LRCHL) and nodular lymphocyte predominant HL (NLPHL)] and in controls. MT expression is significantly and differentially altered in the HL subtypes. NSHL and MCHL show highly increased MT throughout the lymph node. In contrast, MT is barely increased in LRCHL relative to controls. NLPHL shows a distinct pattern of heterogeneous MT with increased MT in nodular areas surrounded by MT-negative tissue. The cellular MT sources are reactive, infiltrating (non-neoplastic) cells, whereas neoplastic cells are devoid of MT. We show for the first time that MT is differentially expressed in subclassified HL.

AB - Metallothionein (MT) expression is considered to be a prognostic factor that promotes tumor resistance to apoptosis. In non-Hodgkin lymphomas, MT is differentially expressed and constitutes a risk factor. We have characterised MT in lymph nodes of Hodgkin lymphoma (HL) [patients with nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte-rich classical HL (LRCHL) and nodular lymphocyte predominant HL (NLPHL)] and in controls. MT expression is significantly and differentially altered in the HL subtypes. NSHL and MCHL show highly increased MT throughout the lymph node. In contrast, MT is barely increased in LRCHL relative to controls. NLPHL shows a distinct pattern of heterogeneous MT with increased MT in nodular areas surrounded by MT-negative tissue. The cellular MT sources are reactive, infiltrating (non-neoplastic) cells, whereas neoplastic cells are devoid of MT. We show for the first time that MT is differentially expressed in subclassified HL.

U2 - 10.1080/10428190802699340

DO - 10.1080/10428190802699340

M3 - Journal article

C2 - 19199157

SN - 1042-8194

VL - 50

SP - 200

EP - 210

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Metallothionein as a useful marker in Hodgkin lymphoma subclassification

Abstract

Access to Document

Fingerprint

Cite this